Saba Capital Management, L.P.'s Form 4 filing
abrdn Life Sciences Investors (HQL) · filed Jun 14, 2024
- Accession no.
- 0001510281-24-000328
- Filed
- Jun 14, 2024, 1:59 PM ET
- Trade date
- Jun 12-13, 2024
- Filing delay
- 2 days
- Rule 10b5-1 plan
- Not checked
This filing lists 2 non-derivative transactions. Open-market purchases total $150.3K. It was filed 2 days after the trade.
Reporting owners
A Form 4 can have several reporting owners, such as a person and a fund they control. Trade tables show the first one.
| Owner | Relationship to the company |
|---|---|
| Saba Capital Management, L.P.CIK 0001510281 | 10% Owner |
| Weinstein BoazCIK 0001608233 | 10% Owner |
Non-derivative securities (Table I)
Acquisitions and disposals of common stock and similar shares, one row per line on the filing.
| Trade date | Security | Transaction | Shares | Price | Value | Shares after | Ownership | Flags |
|---|---|---|---|---|---|---|---|---|
| Jun 12, 2024 | Common Stock | PPurchaseAcquired | +2,400 | $13.88 | +$33,312 | 3,407,612 | Indirect | |
| Jun 13, 2024 | Common Stock | PPurchaseAcquired | +8,467 | $13.82 | +$117,013.94 | 3,416,079 | Indirect |
Footnotes and remarks
Livermore keeps the footnotes that transaction prices refer to, all footnotes of amendments (Form 4/A) and the filing's remarks. Other footnotes, such as how indirect holdings are held or the details of a trading plan, are only in the original on SEC EDGAR.
No transaction price on this filing refers to a footnote.